News-Medical.Net July 28, 2024
In a recent review published in the journal Cell, researchers collate and elucidate recent research and clinical trials highlighting the mechanistic underpinnings and beneficial outcomes of glucagon-like peptide-1 (GLP-1)-based polyagonists. First developed as anti-type 2 diabetes (T2D) interventions, these biochemically engineered drug interventions have presented extraordinary success in the pharmacological treatment of excess body fat, with reductions of 20-30% observed in some cases.
Additionally, their associated benefits of reduced blood glucose content (glycemia), kidney disease, fatty liver, and improved cardiovascular functioning make them a viable alternative to conventional bariatric surgery and underscore significant medical advances in combatting obesity.
Background
Obesity, clinically defined as a body mass index (BMI) > 35 kg/m2, is characterized by excessive body fat and presents one...
Today's Sponsors
Today's Sponsor